◆ Market Data --:--
Commodities
Loading...
📈 Yields & Rates
Loading...
💱 FX Rates
Loading...
📈 Market Pulse
Loading...
🏛 Congress Trades
Loading...
👤 Insider Trades
Loading...
Customize Items

CELLDEX THERAPEUTICS, INC.

CIK: 744218 SIC: 2835
$2.97M
Revenue
$-258.76M
Net Income
-
Gross Margin
-9675.62%
Op. Margin
$-367.67M
Free Cash Flow
Financial Statements Annual (10-K)
Showing 5 of 14 annual reports available (2011 - 2025)
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
+ Total Revenue $2.97M $1.54M $7.02M $6.88M $2.36M $4.65M
Revenue Growth % 92.2% -78.0% 2.0% 192.0% -49.3% nan%
Cost of Revenue - $200.00K $200.00K $300.00K - -
+ Gross Profit - $1.34M $6.82M $6.58M - -
Gross Margin % nan% 87.1% 97.2% 95.6% nan% nan%
Operating Expenses $288.91M $288.91M $202.10M $161.43M $117.59M $75.89M
Research & Development $245.07M $245.07M $163.55M $118.01M $82.26M $53.31M
+ Operating Income $-287.37M $-287.37M $-195.08M $-154.54M $-115.23M $-71.24M
Operating Margin % -9675.6% -18599.8% -2778.9% -2245.3% -4889.0% -1531.8%
Income Before Tax - $-258.76M $-157.86M $-141.43M $-112.33M $-70.74M
Income Tax Expense - - - - - $-227.00K
+ Net Income $-258.76M $-258.76M $-157.86M $-141.43M $-112.33M $-70.51M
Net Margin % -8712.4% -16748.0% -2248.8% -2054.8% -4765.6% -1516.0%
Basic EPS -3.90 -3.90 -2.45 -2.92 -2.40 -1.64
Diluted EPS -3.90 -3.90 -2.45 -2.92 -2.40 -1.64
Basic Shares Outstanding - 66.4M 64.4M 48.4M 47K 43K
Diluted Shares Outstanding - 66.4M 64.4M 48.4M 47K 43K
Breakdown FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Cash & Cash Equivalents $28.87M $28.36M $34.81M $29.43M $39.14M
Short-term Investments $489.70M $696.92M $388.78M $275.52M $369.11M
Other Current Assets $14.08M $21.18M $5.47M $12.39M $2.42M
Total Current Assets $534.66M $747.16M $431.69M $317.69M $410.84M
Property Plant & Equipment $5.33M $4.35M $4.06M $3.75M $3.55M
Intangible Assets $27.19M $27.19M $27.19M $27.19M $27.19M
Other Non-current Assets $13.36M $9.75M $107.00K $104.00K $104.00K
Total Assets $582.98M $792.34M $465.63M $352.74M $444.65M
Accounts Payable $1.18M $3.27M $3.49M $3.34M $1.23M
Accrued Liabilities $47.03M $33.84M $22.03M $12.84M $12.00M
Other Current Liabilities $1.23M $942.00K $3.99M $990.00K $1.55M
Total Current Liabilities $50.99M $39.50M $31.12M $18.61M $16.53M
Other Non-current Liabilities $4.04M $3.47M $4.40M $5.33M $7.35M
Total Liabilities $55.82M $45.34M $36.46M $26.53M $25.18M
Common Stock $67.00K $66.00K $56.00K $47.00K $47.00K
Retained Earnings $-1.81B $-1.56B $-1.40B $-1.26B $-1.14B
Total Stockholders Equity $527.16M $747.00M $429.17M $326.20M $419.48M
Total Liabilities & Equity $582.98M $792.34M $465.63M $352.74M $444.65M
Breakdown TTM
(Dec 31, 2025)
FY 2025
(Dec 31, 2025)
FY 2024
(Dec 31, 2024)
FY 2023
(Dec 31, 2023)
FY 2022
(Dec 31, 2022)
FY 2021
(Dec 31, 2021)
Net Income - $-258.76M $-157.86M $-141.43M - -
Depreciation & Amortization $5.99M $3.38M $3.18M $3.01M $2.90M $3.07M
Stock-based Compensation $64.04M $36.22M $34.24M $23.89M $15.61M $8.95M
Operating Cash Flow $-363.69M $-210.94M $-157.78M $-107.29M $-103.73M $-60.91M
Capital Expenditure $3.97M $2.71M $1.92M $1.82M $1.83M $1.25M
Purchases of Investments $810.40M $384.50M $789.92M $424.56M $188.97M $389.88M
Investing Cash Flow $344.82M $209.07M $-290.13M $-105.78M $89.94M $-216.16M
Stock Issued - - $432.30M $216.22M - $269.89M
Financing Cash Flow $2.85M $2.39M $441.45M $218.46M $4.08M $272.37M
Net Change in Cash $-16.02M $515.00K $-6.46M $5.38M $-9.71M $-4.69M
SEC Filing Format - Data shown as it appears in the Q3 2025 (10-Q) filing Period ended: Sep 30, 2025
Condensed Consolidated Statements of Operations
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Total Revenue - - $1.42M -
Operating Expenses $73.62M - $201.64M -
Research & Development $62.93M - $169.74M -
Operating Income $-73.62M - $-200.21M -
Net Income $-67.04M $-35.84M $-177.44M -
Basic EPS -1.01 - -2.67 -
Diluted EPS -1.01 - -2.67 -
Basic Shares Outstanding $66.42K - $66.40K -
Diluted Shares Outstanding $66.42K - $66.40K -
Condensed Consolidated Balance Sheets
Description Sep 30, 2025 Dec 31, 2024
Cash & Cash Equivalents $36.04M $28.36M
Short-term Investments $547.19M $696.92M
Other Current Assets $21.03M $21.18M
Total Current Assets $604.34M $747.16M
Property Plant & Equipment $4.83M $4.35M
Intangible Assets $27.19M $27.19M
Other Non-current Assets $9.36M $9.75M
Total Assets $648.44M $792.34M
Accounts Payable $4.27M $3.27M
Accrued Liabilities $39.72M $33.84M
Other Current Liabilities $930.00K $942.00K
Total Current Liabilities $46.47M $39.50M
Other Non-current Liabilities $2.54M $3.47M
Total Liabilities $50.08M $45.34M
Common Stock $66.00K $66.00K
Retained Earnings $-1.73B $-1.56B
Total Stockholders Equity $598.36M $747.00M
Total Liabilities & Equity $648.44M $792.34M
Condensed Consolidated Statements of Cash Flows
Description Sep 30, 2025 Sep 30, 2025
Current Prior Year Current YTD Prior Year YTD
Net Income $-67.04M $-35.84M $-177.44M -
Depreciation & Amortization - - $2.56M -
Stock-based Compensation - - $27.31M -
Operating Cash Flow - - $-147.00M -
Capital Expenditure - - $1.43M -
Purchases of Investments - - $329.71M -
Investing Cash Flow - - $153.65M -
Financing Cash Flow - - $1.04M -
Net Change in Cash - - $7.68M -

All values are in USD (United States Dollars). Data is sourced from SEC EDGAR 10-K filings.

Annual data represents full fiscal year results. FY = Fiscal Year ending.

NEWS
Loading article...
NEWS
Loading news...
TRENDING
Loading...